Drugmakers race to develop PCSK9 inhibitors for "bad" cholesterol

08/28/2011 | Reuters

Several drugmakers are working on injectable compounds that inhibit the PCSK9 protein linked to high cholesterol. Regeneron and partner Sanofi lead the race with drug candidate REGN727, an antibody that reduced LDL, or "bad" cholesterol, by more than 60% over four weeks during an early-stage study. PCSK9 inhibitors are expected to be given with cholesterol-lowering drugs among patients not helped by statins alone.

View Full Article in:


Published in Brief: